Navigation Links
ASPIRE Independent Review Board Announces 10 Ways to Protect Participants' Rights in Clinical Drug Trials and Optimize Results From Research
Date:6/9/2008

ASPIRE IRB Is Exhibiting at Bio International Convention in San Diego June

17-20 Currently, over 54,255 Trials with Locations in 154 Countries Are Taking

Place

SAN DIEGO, June 9 /PRNewswire/ -- ASPIRE IRB (http://www.aspire-irb.com), an Independent Review Board (IRB), is responsible for overseeing research and protecting the rights and welfare of people participating in clinical trials. ASPIRE IRB partners with drug manufacturers and research companies to get the best results from clinical drug trials and protect the rights and welfare of participants. "Making sure research is being implemented correctly is critical to the success of the study. Each study is unique. For instance people with Schizophrenia can tolerate a higher dose of particular drugs than people without the disorder. Races, because of genetics, react differently as well," explains Alycia Huston, COO of ASPIRE IRB.

The FDA and HHS regulations empower Independent Review Boards to approve or disapprove research and require modifications. They are made up of physicians, scientists, nonscientists, community members and associates affiliated with the IRB. A clinical trial CANNOT take place without an Independent Review Board.

Hundreds of thousands of people participate in clinical trials with the hope of finding relief and or to help others. Research is essential to finding cures and treatments for conditions and diseases. Being a member of a clinical trial is a big decision. It is essential for people to know their rights and understand how clinical trials work. They follow a defined protocol or study plan. It is designed to protect the health of participants and answer specific research questions.

Participating in clinical trials provides hope, can save lives and help others.

"Clinical trials for Cancer were instrumental in extending my
'/>"/>

SOURCE ASPIRE IRB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Promise of Vicals CMV Vaccine Noted by Independent Experts
2. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
3. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
4. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
5. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
9. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... YORK, Dec. 20, 2010 Health organizations will undergo ... new rules and payment models, continuing cost pressures and ... Industry Issues of 2011 , published today by PwC,s ... of 1,000 U.S. adults, PwC found that consumers don,t ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... 8:30 a.m. Eastern Time on Monday, December 20, to discuss ... in central retinal vein occlusion (CRVO) and the week 52 ... patients with diabetic macular edema (DME).  A press release will ...
Cached Medicine Technology:Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 2Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 3Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 4Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 5Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 6Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 7Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 8Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... October 22, 2014 Isabel Healthcare ... Allied Health Professions (ASAHP) Conference on October 22-24 in ... will participate in a panel discussion on Technology in ... Isabel Healthcare provides a diagnostic decision support tool and ... diagnosis skills of students and clinical learners. The Isabel ...
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
... May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... Bay Shore, Long Island. This Center is the Company,s ... new markets that CRH has targeted for,expansion. The opening ... 2008 bringing the Company,s total number of Centers to ...
... lead unhealthy lifestyles are more likely to suffer from ... population-based study of more than 5,000 men and women ... journal BJU International. Researchers hope the results will help ... can be managed more effectively. , According to ...
... Revenue Increased 70.9% to $9.2 Million, CHENGDU, ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of ... today announced fiscal results for its third quarter ... quarter of 2008 increased 70.9% to approximately,$9.2 million ...
... to be Webcast Live at 2:00 p.m. ET Thursday, ... Inc.,(Nasdaq: CYNO ), a leading developer and manufacturer ... announced that its senior,management will present at the 2008 ... the Hilton New York., Cynosure,s presentation will be ...
... MONTVALE, N.J., May 15 Pain is a ... are an important option,for these patients. Physicians must ... the best outcomes for their patients., To ... the proper,opioid analgesic, the dual journals Current Clinical ...
... mouse model hint of new treatment strategies for the disease ... fat, the kind often found in baked and fried goods, ... The finding by University of California, Los Angeles, scientists is ... mouse model that closely mimics human cancer. , The fat ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 3Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 10Health News:Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference 2Health News:Treat Your Patients' Pain Effectively 2Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: